Angion Biomedica (ANGN) stock has had a difficult run since the company's shares leapt in initial trading after its IPO on Feb. 9, which raised $92m via the issuance of 5.75m shares at a price of $16.
Angion Biomedica Corp. ANGN announced that it has entered into a definitive merger agreement with the privately-held biotech, Elicio Therapeutics, wherein the latter will merge with a wholly-owned ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results